Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jun 26:10:37.
doi: 10.21037/tgh-24-167. eCollection 2025.

Prognostic and monitoring potential of circulating tumor DNA in resectable pancreatic cancer

Knut Jørgen Labori  1   2
Affiliations
Editorial

Prognostic and monitoring potential of circulating tumor DNA in resectable pancreatic cancer

Knut Jørgen Labori. Transl Gastroenterol Hepatol. .
No abstract available

Keywords: Pancreatic cancer; circulating tumor DNA (ctDNA); neoadjuvant chemotherapy; recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-24-167/coif). The author has no conflicts of interest to declare.

Comment on

  • Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.
    Cecchini M, Salem RR, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend JP, Cai G, Chowdhury S, Yugawa D, Tseng R, Mejia Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan SA, Cha C, Billingsley KG, Kunstman JW, Johung KL, Wiess C, Muzumdar MD, Spickard E, Aushev VN, Laliotis G, Jurdi A, Liu MC, Escobar-Hoyos L, Lacy J. Cecchini M, et al. JAMA Oncol. 2024 Aug 1;10(8):1027-1035. doi: 10.1001/jamaoncol.2024.1575. JAMA Oncol. 2024. PMID: 38900452 Free PMC article. Clinical Trial.

References

    1. Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol 2023;20:318-37. 10.1038/s41571-023-00746-1 - DOI - PubMed
    1. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 2018;379:2395-406. 10.1056/NEJMoa1809775 - DOI - PubMed
    1. Maggino L, Malleo G, Marchegiani G, et al. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surg 2019;154:932-42. 10.1001/jamasurg.2019.2277 - DOI - PMC - PubMed
    1. Farnes I, Kleive D, Verbeke CS, et al. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2). BJS Open 2023;7:zrad137. 10.1093/bjsopen/zrad137 - DOI - PMC - PubMed
    1. Stoop TF, Theijse RT, Seelen LWF, et al. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol 2024;21:101-24. 10.1038/s41575-023-00856-2 - DOI - PubMed